Our Current Projects

SPECTA is an EORTC pan-European translational research platform, created to promote development of TR projects in Europe, mainly focusing on the biological aspects of cancer, including molecular profiling and personalised therapy.

Currently, there are several projects in progress within the pipeline, each at different stages. The BioRadon project is actively recruiting patients, while the H&N cohort of MRD has recently been activated for recruitment. The IMMUcan, AYA and Arcagen projects are in the final analysis step.

Recruiting

Recruiting

RP-1828 IMMUCAN

Closed to recruitment – Analysis phase

RP-1843 ARCAGEN

Closed to recruitment – Analysis phase

Closed to recruitment – Analysis phase

RP-1920 BIORADON Recruiting
RP-2148-MRD Activation phase
RP-1828 IMMUCAN Closed to recruitment – Analysis phase
RP-1843 ARCAGEN Closed to recruitment – Analysis phase
RP-1759 AYA Closed to recruitment – Analysis phase

Our Projects in the pipeline

In addition to our ongoing projects, we have a pipeline of exciting initiatives currently in pre-development. These projects hold tremendous potential at advancing molecular understanding of cancer, so that clinicians can selectively target specific patient profiles, paving the way for personalised, ‘best fit’ treatments.

To bring these ideas to life, we are seeking financial partners who share our commitment to driving meaningful progress in cancer research. Explore the descriptions below to learn more about each pipeline project and discover how we can collaborate.

If you are interested in developing a project with us, please reach out to specta@eortc.org

2362 SONAR – In pre-development

Project description

Observational study for assessing treatment and outcome of patients with stage III NSCLC. Main objective is to collect high-quality prospective data of all patients diagnosed with stage III NSCLC to characterize disease profiles of interest within this patient population and to further support cancer research.

Our funders

The EORTC study team and coordinators are currently in the process of securing funding to make this important project a reality. The project will commence once the necessary support is in place.

If you are interested in contributing, we invite you to contact the project manager, alexandra.jouret@eortc.org.

Project description

STARBURST-1 is an extensive translational research program that aims to develop an effective clinical multimodal signature that can predict response to treatment in patients who received standard-of-care neoadjuvant therapy (NAT) and are scheduled for a cystectomy. MRIs and samples (tissue, blood, urine) will be collected before and after NAT for analyses.

Study-coordinators:

  • Alexandra Masson Lecomte, study coordinator
  • Yves Allory, study co-coordinator
  • Lars Dyrskjøt Andersen, study co-coordinator
  • Valeria Panebianco, study co-coordinator
  • Guillaume Grisay, study co-coordinator

Our funders

Starburst-1 owes its realisation to the support of La Ligue contre le cancer and Cepheid. While these contributions have laid a strong foundation, funding for the various Translational Research Projects is still pending. If you are interested in contributing, we invite you to contact the study team at 2418@eortc.org.